SIGLEC1 and neoplasm: Recent studies suggest that CD169+ macrophages in tumor regional lymph nodes are positively associated with favorable prognosis in patients with colorectal cancer, bladder cancer, endometrial carcinoma, or malignant melanoma (65–68).